Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.

Mochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

In this article, we will delve deeply into these questions, providing a comprehensive understanding of Retatrutyd, its ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Counterfeit forms of weight loss and diabetes drugs are endangering consumers, and Oklahoma General Attorney Gentner Drummond wants to take action against what he calls "bad actors" in the ...